PriceTargets.com logo

Diffusion Pharmaceuticals - DFFN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 08/16/2023 05:00 PM ET
+0 (0.00%)
Get New Diffusion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DFFN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DFFN

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Diffusion Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for DFFN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Diffusion Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/16/2022HC WainwrightUpgradeNeutral ➝ Buy$14.25Low
4/7/2022HC WainwrightReiterated RatingNeutralMedium
3/22/2021HC WainwrightReiterated RatingHoldLow
11/17/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
8/12/2020HC WainwrightReiterated RatingBuy$262.50High
3/19/2020HC WainwrightReiterated RatingBuy$262.50High
12/18/2019HC WainwrightLower TargetBuy$750.00 ➝ $262.50Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Diffusion Pharmaceuticals logo
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $4.64
Low: $4.38
High: $6.60

52 Week Range

Now: N/A

Volume

351,000 shs

Average Volume

10,937 shs

Market Capitalization

$8.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Diffusion Pharmaceuticals?

The following sell-side analysts have issued reports on Diffusion Pharmaceuticals in the last twelve months: StockNews.com.
View the latest analyst ratings for DFFN.

What is the current price target for Diffusion Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Diffusion Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Diffusion Pharmaceuticals in the next year.
View the latest price targets for DFFN.

What is the current consensus analyst rating for Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DFFN.

What other companies compete with Diffusion Pharmaceuticals?

Other companies that are similar to Diffusion Pharmaceuticals include Aeterna Zentaris, NuCana, Molecular Templates, Virios Therapeutics and Akari Therapeutics. Learn More about companies similar to Diffusion Pharmaceuticals.

How do I contact Diffusion Pharmaceuticals' investor relations team?

Diffusion Pharmaceuticals' physical mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company's listed phone number is (434) 220-0718 and its investor relations email address is [email protected]. The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com. Learn More about contacing Diffusion Pharmaceuticals investor relations.